A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors
局所進行又は転移性固形癌患者を対象としたROSE12単剤及び抗腫瘍薬併用投与時の安全性及び薬物動態の評価を行う非盲検下第Ia/Ib相用量漸増試験
- NCT番号
- NCT05907980
- 他の登録番号
- jRCT2031230072
- 治験責任医師
- 清水俊雄
- 製薬企業（治験依頼者）
- Chugai Pharma USA, Inc.
- 参加条件
Towards “Five-Stars” Phase 1 Center of Excellence
Department of New Experimental Therapeutics
Early-Phase 1 Drug Development Service